Study of recombinant cytochrome P4502C9 activity with diclofenac by MEKC

被引:16
|
作者
Konecny, Jiri
Jurica, Jan
Tomandl, Josef
Glatz, Zdenek [1 ]
机构
[1] Masaryk Univ, Fac Sci, Dept Biochem, Kamenice 5, CZ-62500 Brno, Czech Republic
[2] Masaryk Univ, Fac Med, Dept Pharmacol, CZ-62500 Brno, Czech Republic
[3] Masaryk Univ, Fac Med, Dept Biochem, CZ-62500 Brno, Czech Republic
关键词
cytochrome P450; diclofenac; drug metabolism; MEKC;
D O I
10.1002/elps.200600560
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 2C9 (CYP2C9) is one of the most important isoforms in human liver involved in the metabolism of a large number of therapeutic agents. The aim of this paper is to demonstrate the applicability of CE for the determination of the enzymatic activity of CYP2C9 with diclofenac as a probe substrate. MEKC with SDS as a pseudostationary phase was used for this purpose. Compared to other assays, the MEKC-based method is rapid, can be automated and requires only a small quantity of enzymes and substrate. Moreover the, enzymatic reaction can be monitored with high sensitivity and repeatability even when the reaction mixture is used for the analysis without any pretreatment. The kinetic study on the given enzymatic reaction was also performed since the basic characterization of drug biotransformation generally begins with the enzyme kinetic analysis of metabolite formation. As a result, the Michaelis constant and maximum reaction velocity were evaluated the, values 3.44 +/- 0.45 gM and 19.78 +/- 0.76 nmol . min(-1)nmol(-1), respectively, were in agreement with the literature data. On the other hand, a slight deviation from typical Michaelis-Menten kinetics with a weak positive cooperativity was found at diclofenac concentrations below 2 gM. The same atypical kinetic behavior of CYP2C9 was also observed by other authors.
引用
收藏
页码:1229 / 1234
页数:6
相关论文
共 50 条
  • [11] A global view of cytochrome P4502C9 pharmacogenetics.
    Lanfear, SL
    Van Booven, DJ
    McLeod, HL
    PHARMACOTHERAPY, 2005, 25 (03): : 472 - 473
  • [12] Gemfibrozil is a potent inhibitor of human cytochrome P4502C9
    Wen, X
    Wang, JS
    Backman, JT
    Kivistö, KT
    Neuvonen, PJ
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (11) : 1359 - 1361
  • [13] Atypical enzyme kinetics observed with cytochrome P4502C9
    Evanchik, MJ
    Carlson, TJ
    DRUG METABOLISM REVIEWS, 2002, 34 : 110 - 110
  • [14] Inhibition of cytochrome P4502C9 activity in vitro by 5-hydroxytryptamine and adrenaline
    Gervasini, G
    Martínez, C
    Agúndez, JAG
    García-Gamito, FJ
    Benítez, J
    PHARMACOGENETICS, 2001, 11 (01): : 29 - 37
  • [15] Inhibitory effect of valproic acid on cytochrome P4502C9 activity in epilepsy patients
    Yasar, Umit
    Gunes, Arzu
    Babaoglu, Melih O.
    Bilir, Erhan
    Zengil, Hakan
    Bozkurt, Atila
    FASEB JOURNAL, 2007, 21 (06): : A1192 - A1192
  • [16] Pharmacogenomic effect of cytochrome P4502C9 polymorphisms in different populations
    Wiwanitkit, Viroj
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (02) : 219 - 222
  • [17] Effects of avasimibe on cytochrome P4502C9 expression in vitro and in vivo
    Sahi, J
    Stern, RH
    Milad, MA
    Rose, KA
    Gibson, G
    Zheng, XX
    Stilgenbauer, L
    Sadagopan, N
    Jolley, S
    Gilbert, D
    LeCluyse, EL
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (12) : 1370 - 1376
  • [18] Is cytochrome P4502C9 genotype associated with NSAID gastric ulceration?
    Martin, JH
    Begg, EJ
    Kennedy, MA
    Roberts, R
    Barclay, ML
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (06) : 627 - 630
  • [19] Implications of cytochrome P4502C9 polymorphism on Warfarin metabolism and dosing
    Redman, AR
    PHARMACOTHERAPY, 2001, 21 (02): : 235 - 242
  • [20] Oxidation of celecoxib by polymorphic cytochrome P4502C9 and alcohol dehydrogenase
    Sandberg, M
    Yasar, Ü
    Strömberg, P
    Höög, JO
    Eliasson, E
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) : 423 - 429